Abbvie, Inc.

Ticker: ABBV

Class Period Start: 04/30/2021

Class Period End: 08/31/2021

Registration Deadline: 06/06/2022

 A class action lawsuit has been filed on behalf of purchasers of the securities of AbbVie Inc. between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”). According to the Complaint, AbbVie Inc. is one of the world’s largest pharmaceutical companies. Its biggest drug, Humira—an anti-inflammatory drug used to treat illnesses such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis (“RA”), and more—was, in 2021 (aside from COVID-19 vaccines), the world’s best-selling prescription drug, with net revenue of more than $20 billion in 2021. Humira accounts for more than a third of AbbVie’s net revenue.

While patents have protected Humira’s blockbuster profits for years, biosimilar drugs will be permitted to enter the market and compete directly with Humira beginning in 2023. As a result, Humira’s sales are widely expected to decline significantly over the next several years—thereby undermining AbbVie’s revenue and earnings.

Accordingly, AbbVie’s future revenue and earnings depend in large part on the Company’s ability to develop new sources of revenue to offset reduced Humira sales. Rinvoq – an anti-inflammatory drug manufactured by AbbVie and used to treat RA and other diseases by inhibiting Janus kinase (“JAK”) enzymes – was touted as one such drug. Rinvoq was initially approved in the United States to treat only moderate to severe RA. However, AbbVie was actively pursuing additional treatment indications and, in 2020, asked the U.S. Food and Drug Administration (the “FDA”) to approve Rinvoq for the treatment of several other diseases, including psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis.

The Complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company’s business and operations. Specifically, the Complaint alleges Defendants misrepresented and/or failed to disclose that:

  • safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors;
  • as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and 
  • therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis. As a result of the alleged wrongful acts and omissions, AbbVie’s securities have experienced a significant decline in market value and AbbVie investors have suffered significant damages.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Purchases

Sales

Please Note

Neither the submission to nor the receipt of information by Lowey Dannenberg or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* Indicates a required field.

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.